Evidence map›Paper›PMID 30255989›Full record

SynthesisStem cells translational medicine2018

Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis.

Manoj M Lalu, Sasha Mazzarello, Jennifer Zlepnig, Yuan Yi Ryan Dong, Joshua Montroy, Lauralyn McIntyre, P J Devereaux, Duncan J Stewart, C David Mazer, Carly C Barron and 2 more

Registry-linked trialOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Stem cells translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05762601 (Cellular precOnditioning for Post-Surgical Myocardial Ischemic Complications - Observational Study), which is not on this map. Cited by 79 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 11 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05762601 unknown statusnot on this mapstarted 2023, after this paper: background citation

Cellular precOnditioning for Post-Surgical Myocardial Ischemic Complications - Observational Study

TypeobservationalSponsorOttawa Hospital Research InstituteRan2023 to 2025Enrolled12ConditionsCardiac Complication, Myocardial Infarction, Myocardial Ischemia, Myocardial Injury
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 11 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Manoj M LaluDepartment of Anesthesiology and Pain Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.ORCID 0000-0002-0322-382X
Sasha MazzarelloBlueprint Translational Research Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Jennifer ZlepnigFaculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Yuan Yi Ryan DongFaculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Joshua MontroyBlueprint Translational Research Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Lauralyn McIntyreBlueprint Translational Research Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.ORCID 0000-0003-1299-5132
P J DevereauxPopulation Health Research Institute, David Braley Cardiac, Vascular, and Stroke Research Institute, Departments of Medicine and Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Duncan J StewartRegenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.ORCID 0000-0002-9113-8691
C David MazerDepartment of Anesthesia, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Department of Physiology, Toronto, Ontario, Canada.
Carly C BarronDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Daniel I McIsaacDepartment of Anesthesiology and Pain Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
Dean A FergussonBlueprint Translational Research Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Ottawa Hospital Research InstituteOttawa Hospital · CAUniversity of Ottawa · CAMcMaster University · CAPopulation Health Research Institute · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preclinical and clinical evidence suggests that mesenchymal stem cells (MSCs) may be beneficial in treating both acute myocardial infarction (AMI) and ischemic heart failure (IHF). However, the safety profile and efficacy of MSC therapy is not well-known. We conducted a systematic review of clinical trials that evaluated the safety or efficacy of MSCs for AMI or IHF. Embase, PubMed/Medline, and Cochrane Central Register of Controlled Trials were searched from inception to September 27, 2017. Studies that examined the use of MSCs administered to adults with AMI or IHF were eligible. The Cochrane risk of bias tool was used to assess bias of included studies. The primary outcome was safety assessed by adverse events and the secondary outcome was efficacy which was assessed by mortality and left ventricular ejection fraction (LVEF). A total of 668 citations were reviewed and 23 studies met eligibility criteria. Of these, 11 studies evaluated AMI and 12 studies evaluated IHF. There was no association between MSCs and acute adverse events. There was a significant improvement in overall LVEF in patients who received MSCs (SMD 0.73, 95% CI 0.24-1.21). No significant difference in mortality was noted (Peto OR 0.68, 95% CI 0.38-1.22). Results from our systematic review suggest that MSC therapy for ischemic heart disease appears to be safe. There is a need for a well-designed adequately powered randomized control trial (with rigorous adverse event reporting and evaluations of cardiac function) to further establish a clear risk-benefit profile of MSCs. Stem Cells Translational Medicine 2018;7:857-866.

Indexed as

Adult Stem CellsCell- and Tissue-Based TherapyHeart FailureHumansMyocardial InfarctionOdds RatioQuality of LifeRisk AssessmentVentricular Function, LeftMyocardial infarctionMyocardial ischemiaStem cellsSystematic review

Identifiers

PMID30255989
PMCPMC6265630
OpenAlexW2893436956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.